Regeneron [REGN] vs Alnylam [ALNY] Detailed Stock Comparison
Regeneron
NASDAQ
Loading...
Alnylam
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Regeneron wins in 12 metrics, Alnylam wins in 6 metrics, with 0 ties. Regeneron appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Regeneron | Alnylam | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 14.37 | -197.18 | Alnylam |
| Price-to-Book Ratio | 1.98 | 224.18 | Regeneron |
| Debt-to-Equity Ratio | 9.04 | 1,093.31 | Regeneron |
| PEG Ratio | 12.57 | -351.53 | Alnylam |
| EV/EBITDA | 12.20 | -452.77 | Alnylam |
| Profit Margin (TTM) | 31.37% | -12.96% | Regeneron |
| Operating Margin (TTM) | 29.64% | -2.09% | Regeneron |
| EBITDA Margin (TTM) | 29.64% | N/A | N/A |
| Return on Equity | 15.34% | -257.83% | Regeneron |
| Return on Assets (TTM) | 6.66% | -2.63% | Regeneron |
| Free Cash Flow (TTM) | $3.54B | $-42.59M | Regeneron |
| Dividend Yield | 0.46% | N/A | N/A |
| 1-Year Return | -50.23% | 62.72% | Alnylam |
| Price-to-Sales Ratio (TTM) | 4.25 | 22.83 | Regeneron |
| Enterprise Value | $54.50B | $56.00B | Alnylam |
| EV/Revenue Ratio | 3.83 | 22.75 | Regeneron |
| Gross Profit Margin (TTM) | 85.58% | 81.52% | Regeneron |
| Revenue per Share (TTM) | $133 | $19 | Regeneron |
| Earnings per Share (Diluted) | $39.66 | $-2.48 | Regeneron |
| Beta (Stock Volatility) | 0.33 | 0.25 | Alnylam |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Regeneron vs Alnylam Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Regeneron | 0.57% | 0.74% | 2.78% | 2.80% | -18.45% | -21.28% |
| Alnylam | 0.88% | 9.24% | 38.25% | 69.90% | 60.16% | 87.88% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Regeneron | -50.23% | -10.45% | -8.09% | -2.31% | 2,289.64% | 6,594.41% |
| Alnylam | 62.72% | 87.54% | 222.14% | 314.75% | 3,084.89% | 4,708.77% |
Performance & Financial Health Analysis: Regeneron vs Alnylam
| Metric | REGN | ALNY |
|---|---|---|
| Market Information | ||
| Market Cap | $60.39B | $56.22B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 917,617 | 1,429,933 |
| 90 Day Avg. Volume | 931,976 | 1,106,691 |
| Last Close | $563.00 | $438.93 |
| 52 Week Range | $476.49 - $1,211.20 | $205.87 - $439.29 |
| % from 52W High | -53.52% | -0.08% |
| All-Time High | $1,211.20 (Aug 26, 2024) | $439.37 (Aug 08, 2025) |
| % from All-Time High | -53.52% | -0.10% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | 0.17% |
| Quarterly Earnings Growth | -0.03% | 0.17% |
| Financial Health | ||
| Profit Margin (TTM) | 0.31% | -0.13% |
| Operating Margin (TTM) | 0.30% | -0.02% |
| Return on Equity (TTM) | 0.15% | -2.58% |
| Debt to Equity (MRQ) | 9.04 | 1,093.31 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $287.55 | $1.91 |
| Cash per Share (MRQ) | $72.04 | $21.80 |
| Operating Cash Flow (TTM) | $4.74B | $-15,539,000 |
| Levered Free Cash Flow (TTM) | $2.85B | $85.71M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.46% | N/A |
| Last 12-Month Dividend | $2.64 | N/A |
Valuation & Enterprise Metrics Analysis: Regeneron vs Alnylam
| Metric | REGN | ALNY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 14.37 | -197.18 |
| Forward P/E | 12.57 | -351.53 |
| PEG Ratio | 12.57 | -351.53 |
| Price to Sales (TTM) | 4.25 | 22.83 |
| Price to Book (MRQ) | 1.98 | 224.18 |
| Market Capitalization | ||
| Market Capitalization | $60.39B | $56.22B |
| Enterprise Value | $54.50B | $56.00B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.83 | 22.75 |
| Enterprise to EBITDA | 12.20 | -452.77 |
| Risk & Other Metrics | ||
| Beta | 0.33 | 0.25 |
| Book Value per Share (MRQ) | $287.55 | $1.91 |
Financial Statements Comparison: Regeneron vs Alnylam
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | REGN | ALNY |
|---|---|---|
| Revenue/Sales | $3.03B | $773.69M |
| Cost of Goods Sold | $464.30M | $142.95M |
| Gross Profit | $2.56B | $630.74M |
| Research & Development | $1.34B | $323.62M |
| Operating Income (EBIT) | $591.70M | $-16.20M |
| EBITDA | $900.90M | $35.44M |
| Pre-Tax Income | $905.00M | $-35.36M |
| Income Tax | $96.30M | $30.92M |
| Net Income (Profit) | $808.70M | $-66.28M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | REGN | ALNY |
|---|---|---|
| Cash & Equivalents | $3.09B | $1.02B |
| Total Current Assets | $17.57B | $3.27B |
| Total Current Liabilities | $3.57B | $1.08B |
| Long-Term Debt | $2.70B | $1.26B |
| Total Shareholders Equity | $29.39B | $115.44M |
| Retained Earnings | $32.38B | $-7.35B |
| Property, Plant & Equipment | N/A | $695.92M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | REGN | ALNY |
|---|---|---|
| Operating Cash Flow | $1.36B | $-145.39M |
| Capital Expenditures | N/A | $-8.97M |
| Free Cash Flow | $773.60M | $-127.28M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-1.05B | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | REGN | ALNY |
|---|---|---|
| Shares Short | 2.07M | 3.38M |
| Short Ratio | 2.06 | 3.70 |
| Short % of Float | 0.02% | 0.03% |
| Average Daily Volume (10 Day) | 917,617 | 1,429,933 |
| Average Daily Volume (90 Day) | 931,976 | 1,106,691 |
| Shares Outstanding | 109.62M | 129.29M |
| Float Shares | 98.02M | 126.15M |
| % Held by Insiders | 0.02% | 0.04% |
| % Held by Institutions | 0.94% | 0.97% |
Dividend Analysis & Yield Comparison: Regeneron vs Alnylam
| Metric | REGN | ALNY |
|---|---|---|
| Last 12-Month Dividend | $2.64 | N/A |
| Last 12-Month Dividend Yield | 0.46% | N/A |
| 3-Year Avg Annual Dividend | $0.88 | N/A |
| 3-Year Avg Dividend Yield | 0.14% | N/A |
| 3-Year Total Dividends | $2.64 | N/A |
| Ex-Dividend Date | Aug 18, 2025 | N/A |